X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/15/2862656/0/en/Invivyd-Receives-Healthcare-Common-Procedure-Coding-System-HCPCS-Reimbursement-Codes-from-the-U-S-Centers-for-Medicare-Medicaid-Services-CMS-Covering-PEMGARDA.html
https://www.globenewswire.com/news-release/2024/04/12/2862118/0/en/Invivyd-Announces-CEO-Transition.html
https://www.globenewswire.com/news-release/2024/04/04/2858181/0/en/Invivyd-Provides-PEMGARDA-Launch-Update-and-Announces-2024-Net-Product-Revenue-Guidance-in-the-Range-of-150-Million-to-200-Million.html
https://www.globenewswire.com/news-release/2024/03/28/2853831/0/en/Invivyd-Reports-Full-Year-2023-Financial-Results-and-Recent-Business-Highlights.html
https://www.fiercepharma.com/pharma/invymabs-covid-preventative-pemgarda-nabs-fda-emergency-nod-immunocompromised-virus
https://www.globenewswire.com/news-release/2024/03/22/2851123/0/en/Invivyd-Announces-Interim-Exploratory-Data-on-VYD222-from-Ongoing-CANOPY-Clinical-Trial.html
https://www.globenewswire.com/news-release/2024/03/22/2851117/0/en/Invivyd-Announces-FDA-Authorization-for-Emergency-Use-of-PEMGARDA-Formerly-VYD222-for-Pre-exposure-Prophylaxis-PrEP-of-COVID-19.html
https://www.globenewswire.com//news-release/2024/02/05/2823840/0/en/Invivyd-to-Participate-at-the-Guggenheim-Healthcare-Talks-6th-Annual-Biotechnology-Conference.html
https://www.globenewswire.com//news-release/2024/01/03/2803175/0/en/Invivyd-Submits-Request-for-Emergency-Use-Authorization-EUA-to-U-S-FDA-for-VYD222-for-the-Pre-exposure-Prevention-of-COVID-19-in-Immunocompromised-Adults-and-Adolescents.html
https://endpts.com/invivyd-requests-emergency-use-authorization-for-covid-19-preventive-antibody-among-immunocompromised/
Market Place
Share 
